Table 2.
Commonly used therapy in children with CP, 27 groups, n = 986.
| References | Treatments | n | Age (months) | Treatment duration (months) | GMFM initial (%) | GMFM final (%) | Gain GMFM | ENE | GMFMER | |
|---|---|---|---|---|---|---|---|---|---|---|
| Pennington et al. 2020 | (46) | SDR | 137 | 78.5 | 12.0 | 59.0 | 63.6 | 4.6 | 0.6 | 7.5 |
| Wright et al. 1998 | (34) | SDR | 12 | 57.8 | 12.0 | 51.9 | 64.0 | 12.1 | 1.3 | 9.5 |
| Law et al. 1997 | (47) | SDR | 18 | 51.6 | 12.0 | 48.2 | 57.8 | 9.6 | 1.6 | 6.2 |
| van Schie et al. 2011 | (48) | SDR | 24 | 79.0 | 12.0 | 56.6 | 60.9 | 4.3 | 0.5 | 8.0 |
| van Schie et al. 2005 | (49) | SDR | 9 | 65.3 | 12.0 | 62.8 | 71.5 | 8.7 | 1.3 | 8.7 |
| Sargut et al. 2021 | (50) | SDR | 77 | 72.0 | 24.0 | 70.0 | 77.0 | 7.0 | 2.9 | 2.4 |
| Summers et al. 2019 | (51) | SDR | 137 | 72.0 | 24.0 | 59.0 | 66.2 | 7.2 | 1.3 | 5.3 |
| Zhan et al. 2020 | (52) | SDR | 86 | 74.4 | 19.9 | 53.0 | 59.1 | 6.1 | 0.8 | 7.4 |
| McLaughlin et al. 1998 | (38) | SDR | 21 | 76.8 | 12.0 | 70.3 | 75.2 | 4.9 | 1.0 | 4.9 |
| Nordmark, Jarnlo, et Hägglund 2000 | (53) | SDR | 18 | 51.6 | 12.0 | 48.2 | 57.8 | 9.6 | 1.6 | 6.2 |
| Steinbok et al. 1997 | (31) | SDR | 14 | 50.0 | 9.0 | 60.7 | 72.0 | 11.3 | 2.2 | 5.2 |
| Mean | 66.3 | 14.6 | 58.2 | 65.9 | 7.8 | 1.4 | 6.5 | |||
| SD | 11.5 | 5.3 | 7.6 | 7.0 | 2.7 | 0.7 | 2.0 | |||
| 66.3 | 14.6 | 58.2 | 65.9 | 7.8 | 1.4 | 6.5 | ||||
| Colovic et al. 2012 | (54) | BT | 16 | 49.0 | 6.0 | 67.8 | 70.9 | 3.1 | 2.1 | 1.5 |
| Chaturvedi et al. 2013 | (41) | PT + BT | 18 | 51.6 | 6.0 | 52.0 | 59.0 | 7.0 | 1.03 | 6.8 |
| Linder et al. 2001 | (55) | BT | 25 | 60.0 | 12.0 | 54.9 | 71.1 | 6.2 | 1.3 | 4.9 |
| Moore et al. 2008 | (56) | BT | 30 | 63.6 | 24.0 | 66.5 | 71.8 | 5.3 | 2.6 | 2.0 |
| Chang et al. 2017 | (57) | BT | 71 | 64.8 | 5.3 | 70.5 | 73.7 | 3.2 | 0.9 | 3.5 |
| Kim, Rha, et Park 2020 | (58) | BT | 29 | 85.2 | 3.5 | 78.6 | 81.2 | 3.5 | 0.3 | 10.6 |
| Matsuda et al. 2018 | (59) | BT | 9 | 75.6 | 2.8 | 62.3 | 63.3 | 1.0 | 0.2 | 4.6 |
| Polovina et al. 2010 | (40) | PT + BT | 12 | 23.0 | 56.0 | 20.8 | 58.9 | 38.1 | 6.0 | 6.3 |
| Mean | 59.1 | 14.4 | 59.2 | 68.7 | 8.4 | 1.9 | 5.0 | |||
| SD | 18.8 | 18.2 | 17.7 | 7.8 | 12.1 | 2.0 | 2.9 | |||
| Kwon et al. 2015 | (27) | Hippotherapy | 45 | 68.4 | 2.0 | 60.8 | 63.5 | 2.7 | 0.2 | 12.9 |
| Kwon et al. 2011 | (28) | Hippotherapy | 16 | 73.2 | 2.0 | 70.4 | 73.7 | 3.3 | 0.2 | 13.8 |
| Mean | 70.8 | 2.0 | 65.6 | 68.6 | 3.0 | 0.2 | 13.3 | |||
| SD | 3.4 | 0.0 | 6.8 | 7.2 | 0.4 | 0.0 | 0.6 | |||
| Sun et al. 2022 | (60) | Stem cell | 23 | 45.6 | 12.0 | 50.3 | 58.8 | 8.6 | 2.4 | 3.6 |
| Sun et al. 2022 | (60) | Stem cell | 25 | 43.2 | 12.0 | 48.1 | 54.7 | 6.6 | 2.6 | 2.6 |
| Sun et al. 2022 | (60) | Stem cell | 20 | 43.2 | 12.0 | 49.0 | 58.0 | 9.0 | 2.7 | 3.4 |
| Yousif et al. 2023 | (61) | Stem cell | 35 | 51.6 | 3.0 | 29.0 | 32.7 | 3.7 | 0.2 | 17.6 |
| Sun et al. 2017 | (24) | Stem cell | 32 | 38.4 | 12.0 | 48.9 | 56.4 | 7.5 | 3.6 | 2.1 |
| Huang et al. 2018 | (42) | Stem cell | 27 | 87.6 | 24.0 | 85.0 | 97.7 | 12.7 | 1.9 | 6.6 |
| Mean | 51.6 | 12.5 | 51.7 | 59.7 | 8.0 | 2.2 | 6.0 | |||
| SD | 18.2 | 6.7 | 18.2 | 21.0 | 3.0 | 1.1 | 5.9 |
BT, botulinum toxin, ENE, expected natural evolution; GMFM, gross motor function measure; GMFMER, gross motor function measure evolution ratio; PT, physical therapy; SDR, selective dorsal rhizotomy.